Full Press Release Details
Accessibility: Skip TopNav
Summit Therapeutics Files US Annual Report on Form 20F
April 13, 2018 09:45 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Therapeutics plc
("Summit", or the "Company")
Summit Therapeutics Files US Annual Report on Form 20-F
Oxford, UK, and Cambridge, MA, US, 13 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT) provides notification that the Company has today filed its US Annual Report on Form 20-F for the year ended 31 January 2018 with the US Securities and Exchange Commission ("SEC").
The Form 20-F is available to download, either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | ksharma@macbiocom.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | summit@consilium-comms.com | |
| Philippa Gardner |